Speed and power-related gene polymorphisms associated with playing position in elite soccer players

AUTHORS: Miroslav Petr¹, Dan Thiel¹, Kvapilová Kateřina²,³, Petr Brož²,³, Tomáš Malý¹, František Zahálka¹, Pavlína Vostatková¹, Michal Wilk⁵, Jakub Chycki¹, Petr Stastny¹

¹ Faculty of Physical Education and Sport, Charles University, Czech republic
² Institute of Applied Biotechnologies, Prague, Czech Republic
³ Faculty of Science Charles University, Prague, Czech Republic
⁴ Second Faculty of Medicine Charles University, Prague, Czech Republic
⁵ Institute of Sport Sciences, The Jerzy Kukuczka Academy of Physical Education in Katowice, Katowice, Poland

ABSTRACT: Heritability studies on sport-related traits accepted that endurance, speed, power, and strength abilities include an active genetic predisposition to elite soccer participation. This study evaluates the influence of selected genetic variants on performance in speed, power, and strength laboratory tests on a group of elite soccer players, including their playing position. A ninety-nine male elite soccer players were compared to controls (n = 107) and tested for quadriceps and hamstrings isokinetic strength at speed 60°/s, 180°/s, and 300°/s, jump performance, and genotypes of ACTN3 (R577X, rs1815739), ACE (I/D, rs1799752), NOS3 (Glu298Glu, rs1799983), AMPD1 (34C/T, rs17602729), UCP2 (A195Val, rs660339), BDKRB2 (−9/+9, rs5810761) and IL1RN (VNTR 86-bp). The ACTN3 XX homozygotes in defenders had lower quadriceps and hamstring isokinetic strength in all tested speeds than ACTN3 RX and RR genotypes (p < 0.05). The ACTN3 RR homozygotes in defenders had higher quadriceps strength in all tested velocities than the RX heterozygotes (p < 0.05). We also found other associations between playing-position in soccer and increased strength of lower limbs for AMPD1 CC and NOS3 Glu/Glu genotypes, and IL1RN*2 allele carriers. Total genetic score regression explained 26% of the variance in jump performance and isokinetic strength. The ACTN3 R allele, NOS3 Glu/Glu genotypes, and IL1RN*2 allele pre-disposed the attackers and defenders playing position in elite soccer, where those positions have higher strength and power measures than midfielders. Midfielders have lower strength and power conditions than other playing positions without relation to strength and power genes.

CITATION: Petr M, Thiel D, Katelina K et al. Speed and power-related gene polymorphisms associated with playing position in elite soccer players. Biol Sport. 2022;39(2):355–366.

INTRODUCTION

Elite soccer is highly competitive, and only a minority of players can participate in the world’s best soccer leagues. This fact also relates to the high complexity of soccer requirements, including technical, tactical, psychological, and physiological domains. The main physiological factors are the combination of endurance and speed [1–4], like repeated short sprints [5, 6]; moreover, current soccer increases strength and power requirements. Based on estimations of heritability studies on sport-related traits, it is generally accepted that endurance, speed-power, and strength abilities include a genetic determination [7–10], which might be explained at least partly through the genetics of muscle fibers specificity [11, 12].

Among various physical constraints for soccer players, the knee extensors and flexors’ concentric and eccentric strength correlate with soccer sprints [13–15] and deceleration ability [16] and differs by soccer-playing positions [17, 18]. Therefore, the knee flexors and extensors’ force at different speeds can generally explain the necessary force-velocity predisposition of elite players [19], which are possible predictors of soccer players’ agility and jump performance [20, 21]. Concerning the force-velocity profile, the soccer performance is specific by high speed running and sprinting [1, 22], acceleration and deceleration [23], isokinetic strength [18], and vertical jump performance [24, 25]. Since there is a clear cue between playing position and conditioning specificity, it is still unknown whether the force-velocity specificity might be genetically determined for playing position in the elite soccer level. On the other hand, some genetic markers have been associated with soccer attackers’ metabolic traits [26].

Many candidate gene studies have investigated the influence of several genetic polymorphisms on athletes’ speed, power, and strength performance during the past few years [7, 27]. In those studies, positive associations of “speed, power, and strength” genotypes have been found in groups of soccer players for the ACTN3 gene [28–32].
or the PPARA gene [32–34]. Recently, the metanlyses of Weyerstrass et al. (2018) identified nine genetic polymorphisms for power phenotype: ACE (rs4363, rs1799752), ACTN3 (rs1815739), AGT (rs699), ILE6-174 (rs1800795), MnSOD (rs1799725), NOS3 (rs1799983, rs2070744) and SOD2 (rs4880) [35], whereas some of them overlap with findings of current review from 2020 [36].

Since there are known genetic determinants for soccer conditioning, there is a lack in understanding genetic determinants for elite soccer level and playing position. Therefore, this study evaluates the influence of genetic variants on performance in speed, power, and strength laboratory tests on a group of elite soccer players concerning their playing position (attacker, defender, midfielder, and goalkeeper). We target the seven gene polymorphisms previously associated with speed, power, and strength ACTN3 (R577X, rs1815739), ACE (I/D, rs1799752), NOS3 (Glu298Asp, rs1799983), AMPD1 (34C/T, rs17602729), UCP2 (Ala55Val, rs660339), BDKRB2 (+9/-9, rs5810761) and IL1RN (VNTR 86-bp).

**MATERIALS AND METHODS**

We performed a cross-sectional study with genotyping, vertical jumps, and isokinetic measurement of knee flexion and extension at three different angular speeds. Before the measurement, there was no training session or other demanding physical activity. The genotype samples were gathered before the participant general warm-up, which included 5 to 10 minutes of aerobic exercise on a treadmill/bike ergometer up to 140 beats per minute, followed by 5 to 10 minutes of individual static stretching, and 5 to 10 minutes of dynamic stretching presented by hops and dynamic lunges. After the warming-up, all players underwent vertical jump testing, followed by testing on an isokinetic dynamometer with 3 minutes rest interval between individual attempts.

**Subjects**

A ninety-nine Caucasian male soccer players (25.4 ± 4.51 y, 181.4 ± 6.11 cm, 77.4 ± 7.22 kg, Supplementary material Table S1) were recruited from five professional Czech soccer teams participating in the first (88 soccer players) and second national (11 soccer players) soccer league. Fifteen players reached the level of playing in the national team. For later frequency comparison of genotypes and alleles, we used 107 Czech healthy controls (from age 18 to 65) from whole-genome sequencing Czech national project Enigma, CZ.01.1.02/0.0/0.0/16_084/0010360. We calculated most represent allele frequency from targeted gene sites, which were used as a reference in our study. We could not analyze some of the hotspots due to the sequencing kit’s limitations, uncovered regions, and low mapping quality. Some of the genes cannot be studied due to the repetitive areas, which cause a wildly inaccurate variant calling process. All subjects signed informed consent at the beginning of the study participation, approved by the Ethics Committee of Faculty of Physical Education, Charles University (No. 145/2016, issued on October 21, 2016).

**Vertical jump testing**

The measurement was performed using the force plates (Kistler 8611, Switzerland) with a sampling frequency of 1000 Hz for three types of standardized vertical jumps, countermovement jump with the support of upper limbs swing, countermovement jump without hands on the waist, and a squat jump. Each jump test was repeated three to five times based on the subject’s choice, with at least 10 seconds between each jump and the jump type. The data were processed by BioWare software (Kistler Holding AG, Winterthur, Switzerland) and further calculation of the maximum height of the jump, the maximum force, the maximum force per kg of bodyweight [N/kg], and the achieved impulse of force per kg of the subject’s body weight [N·s/kg].

**Isokinetic strength**

Knee extensors and flexors strength was measured at three different angular velocities of 60°/s, 180°/s, and 300°/s using isokinetic dynamometer Cybex Human Norm (Cybex Norm®, Humac, CA, USA) and manufactural software (HUMAC2015®, version 15.000.0044). Subjects performed two repetitions for each angular velocity with 30 s rest between the velocities. During the testing, subjects were verbally encouraged and had full visual contact with the screen showing the current performance level. The extracted data included peak force [Nm] and peak force per kg [Nm/kg] at the concentric phases.

**Genotyping**

Molecular genetic analysis was performed in the Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague. We performed genotyping with DNA samples obtained from epithelial mouth cells collected by a trained individual by cheek brushes (microRheologics, Italy) against the inside of each subject's cheek for approximately 15 s. Subjects were asked not to consume any food or drink in the 30 minutes before sample collection [37]. Cheek brushes were air-dried for at least 8 hours and later stored at -80°C until the DNA extraction, which was performed for a maximum of 2 weeks after the collection. The head of every cheek brush was cut and insert into a screw 2 ml cap tube before the extraction. The head of every cheek brush was cut and insert into a screw 2 ml cap tube before the extraction. DNA was extracted using the isolation kit QIAamp DNA Mini Kit (QIAGen, Germany) according to the manufacturer's instructions, with minor adjustments. Extracted samples were stored at -80°C. The DNA samples were quantified using a Polymerase chain reaction method (PCR) based on previous studies [38, 39]; the procedure details are in Supplementary material Tables S2 and S3. The gradient thermocycler Labcypher (SensoQuest, Germany) was used for PCR reaction. The digested product was visualized by 3% agarose gel electrophoresis in the horizontal electrophoresis device HU10 (SCIEnT-PLA, England) and identified by ethidium bromide staining [40]. Software visualization was performed by the UV light device G: BOX Chemi HR16 (Syngene, England).
The combined influence of the studied polymorphisms
The combined influence of the studied polymorphisms for each soccer player was done using the total genetic score (TGS) by Williams and Folland algorithm [41], where the raw score was transformed to a scale of 0–100: TGS = (100/14) × (GS_{ACE} + GS_{ACTN3} + GS_{BDKRB2} + GS_{NOS3} + GS_{AMPD1} + GS_{UCP2} + GS_{IL1RN}). In this calculation, 14 results from multiplying 7 (the number of studied polymorphisms) by 2 (the score is given to the optimal explosive-leg-strength genotype, where the score given to the optimal strength and power genotype is described in Table 1. The TGS was also calculated for genotypes with phenotype significant results TGS_{sgq}, where TGS_{sgq} = (100/2 × n) × (GS 1st gene + GS 2nd gene + GS n gene). In this calculation n is the number of genes.

| Genotype | Total genetic score count |
|----------|---------------------------|
| ACE (I/D) | 0 = II, 1 = ID, 2 = DD |
| ACTN3 (R577X) | 0 = XX, 1 = RX, 2 = RR |
| BDKRB2 (9/+9) | 0 = +9 + 9, 1 = +9 – 9, 2 = –9 – 9 |
| NOS3 (Glu298Asp) | 0 = Asp/Asp, 1 = Glu/Asp, 2 = Glu/Glu |
| AMPD1 (Gln12X) | 0 = TT, 1 = CT, 2 = CC |
| UCP2 (Ala55Val) | 0 = CC, 1 = CT, 2 = TT |
| IL1RN (VNTR 86-bp) | 0 = 1/1 or 1/3, 1 = 1/2 or 2/3, 2 = 2/2 |

Statistical Analyses
NCSS statistical software (NCSS, USA) was used to calculate Hardy-Weinberg equilibrium and chi-square analysis for testing the allele frequencies determined by gene counting. We used Chi-square analysis to compare genotype distribution, allele frequencies between the group of soccer players and healthy, and frequencies concerning the playing position inside the soccer players group, where p values of < 0.05 were considered statistically significant. The regression analyses, correlation, and group comparison have been performed in STATISTICA software (13.5. TIBCO software, Palo Alto, CA, USA), with a statistical significance level set up for 0.05. The Kolmogorov Smirnov test has calculated the data normality.

One way ANOVA was used to compare performance differences by genotype groups of soccer players (isokinetic/jump performance × genotype), and the two way ANOVA has been used to compare performance differences between genotypes in each playing position (isokinetic/jump performance × genotype × playing position) considering effect size by partial eta square ($\mu^2$) and differences by Unequal HSD post hoc test. $\mu^2$ was considered 0.02–0.12, 0.13–0.25, and $>0.26$ as weak, moderate, and strong associations, respectively [42]. The two way ANOVA has been performed only in the sub-groups with n above 6.

A Spearman correlation coefficient and multiple linear regression model with a step-down (backward) procedure were used to explore the predictive role of the TGS variable with correlated muscle-strength and jump performance phenotypes. The TGS was calculated for all analyzed genotypes and for genotypes with phenotype significant results – TGS_{sgq}.

RESULTS
Physiological studies
The data from subgroups did not show disruption of normality. One way ANOVA showed differences in m. quadriceps strength among positions at 60°/s ($F_2, 181 = 7.3, p < 0.001, \mu^2 = 0.08$), 180°/s ($F_2, 181 = 6.7, p < 0.001, \mu^2 = 0.04$) and 300°/s ($F_2, 170 = 8.6, p < 0.001, \mu^2 = 0.10$) in whole group, where midfield players resulted in lower quadriceps strength than other playing positions (Figure 1). The hamstring strength resulted in difference at 60°/s ($F_2, 181 = 6.4, p < 0.001, \mu^2 = 0.04$), 180°/s ($F_2, 181 = 5.9, p = 0.0081, \mu^2 = 0.06$) and 300°/s ($F_2, 170 = 6.5, p < 0.001, \mu^2 = 0.07$) in whole group, where midfield players resulted in lower hamstring strength than other playing positions (Supplementary material Figure S1).

Case-control genetic studies
All genotype data did not disrupt the Hardy-Weinberg equilibrium, and only NOS3 Glu298Asp differ in the allelic frequency in defenders, where defenders have higher Glu allele frequency than controls (Table 2). The ACE ID, BDKRB2 +9/-9, and IL1RN VNTR polymorphisms did not have reference values in our control group because genotyping was not available in these polymorphisms; therefore, this comparison was not possible (Table 2). We identified no subjects in the following subgroups: ACTN XX in attackers, NOS3 Asp/Asp in attackers and goalkeepers, AMPD1 TT in all subjects, and IL1RN*2/IL1RN*2 in goalkeepers (Table 2). Chi-square analysis of genotype and allele distribution is in Table 2.

Genotype-phenotype studies
The genotype differences were found in ACTN3 gene between quadriceps strength at 60°/s ($F_2, 156 = 4.8, p = 0.009, \mu^2 = 0.09$), 180°/s ($F_2, 156 = 3.7, p = 0.026, \mu^2 = 0.16$) and 300°/s ($F_2, 146 = 7.04, p = 0.001, \mu^2 = 0.08$) in whole group, where XX genotypes resulted in lower quadriceps strength than RX heterozygotes and RR homozygotes whereas RR homozygotes has higher values than other genotypes (Figure 2). The ACTN3 genotypes differ also among hamstring strength at 60°/s ($F_2, 156 = 3.2, p = 0.042, \mu^2 = 0.04$) and 300°/s ($F_2, 147 = 4.1, p < 0.017, \mu^2 = 0.05$) in whole group, where XX genotype resulted in lower quadriceps strength than RX heterozygotes and RR homozygotes and RR homozygotes (Figure 1).
| Genotype / allele / comparison type | Defenders | Attackers | Goalkeepers | Midfielders | All | Controls |
|-----------------------------------|-----------|-----------|-------------|-------------|-----|----------|
|                                   | n 31      | 15        | 14          | 39          | 99  | 107      |
| Allele n (%)                      |           |           |             |             |     |          |
| R                                 | 35 (56.1) | 22 (73.3) | 14 (50.0)   | 47 (60.2)   | 118 (59.6) | 128 (59.8) |
| X                                 | 27 (43.5) | 8 (26.7)  | 14 (50.0)   | 31 (39.7)   | 80 (40.4)  | 86 (40.2)  |
| ACTN3 n (%)                       |           |           |             |             |     |          |
| p Compared to controls            | 0.636     | 0.154     | 0.321       | 0.945       | 0.964 |          |
| p Compared to all                 | 0.661     | 0.150     | 0.335       | 0.920       | 0.920 |          |
| R577X Genotype n (%)              |           |           |             |             |     |          |
| p Compared to controls            | 0.765     | 0.254     | 0.840       | 0.735       | 0.958 |          |
| p Compared to all                 | 0.857     | 0.241     | 0.124       | 0.615       | 0.615 |          |
| NOS3 Glu298Asp Genotype n (%)     |           |           |             |             |     |          |
| p Compared to controls            | 0.031*    | 0.189     | 0.264       | 0.870       | 0.069 |          |
| p Compared to all                 | 0.322     | 0.652     | 0.787       | 0.229       | 0.229 |          |
| AMPD1 Genotype n (%)              |           |           |             |             |     |          |
| p Compared to controls            | 0.966     | 0.672     | 0.440       | 0.309       | 0.357 |          |
| p Compared to all                 | 0.551     | 0.976     | 0.720       | 0.720       | 0.720 |          |
| 34C/T Genotype n (%)              |           |           |             |             |     |          |
| p Compared to controls            | 0.733     | 0.415     | 0.210       | 0.335       | 0.635 |          |
| p Compared to all                 | 0.511     | 0.296     | 0.323       | 0.547       | 0.547 |          |
| UCP2 Vla55Val Genotype n (%)      |           |           |             |             |     |          |
| p Compared to controls            | 0.530     | 0.594     | 0.235       | 0.402       | 0.665 |          |
| p Compared to all                 | 0.670     | 0.528     | 0.187       | 0.762       | 0.762 |          |
| +9                                | 32 (51.6) | 15 (50.0) | 11 (39.3)   | 36 (46.2)   | 94 (47.5) |          |
| -9                                | 30 (48.4) | 15 (50.0) | 17 (60.7)   | 42 (53.8)   | 104 (52.5) |          |
| p Compared to controls            | 0.569     | 0.796     | 0.416       | 0.843       | 0.843 |          |
| p Compared to all                 | 0.569     | 0.796     | 0.416       | 0.843       | 0.843 |          |
| IL1RN*1 Genotype n (%)            |           |           |             |             |     |          |
| p Compared to controls            | 0.280     | 0.982     | 0.189       | 0.794       |        |          |
| p Compared to all                 | 0.280     | 0.982     | 0.189       | 0.794       |        |          |
| p Compared to all                 | 0.280     | 0.982     | 0.189       | 0.794       |        |          |
| IL1RN Genotype (%)                |           |           |             |             |     |          |
| p Compared to controls            | 0.135     | 0.835     | 0.643       | 0.104       | 0.104 |          |
| p Compared to all                 | 0.135     | 0.835     | 0.643       | 0.104       | 0.104 |          |
| p Compared to all                 | 0.135     | 0.835     | 0.643       | 0.104       | 0.104 |          |
| +/−                                  |           |           |             |             |     |          |
| p Compared to controls            | 0.374     | 0.782     | 0.267       | 0.836       |        |          |
| p Compared to controls            | 0.374     | 0.782     | 0.267       | 0.836       |        |          |
| p Compared to all                 | 0.374     | 0.782     | 0.267       | 0.836       |        |          |

*p = the "p" values of the Chi-square test, * statistically significant difference according to the Chi-square test.
Speed and power genes in soccer players

Further differences were found for ACTN3 genotypes and playing position interaction for quadriceps strength at speed of 60°/s ($F_{3,151} = 3.2, p = 0.025, \mu^2 = 0.06$), speed of 180°/s ($F_{3,151} = 5.05, p = 0.002, \mu^2 = 0.09$) and 300°/s ($F_{3,141} = 3.2, p = 0.024, \mu^2 = 0.06$), where post hoc test showed that RR genotype in defenders position had higher quadriceps strength than other genotype groups in each tested speed and XX genotype in defenders had lower quadriceps strength than other genotype groups in each tested speed (Figure 1). No difference among genotypes has been observed in midfielders and for the attackers.

The differences in ACTN3 genotypes and playing position interaction were found for hamstring strength at speed of 60°/s ($F_{3,151} = 2.4, p = 0.05, \mu^2 = 0.05$), speed of 180°/s ($F_{3,151} = 2.9, p = 0.034, \mu^2 = 0.06$) and 300°/s ($F_{3,142} = 8.2, p = 0.047, \mu^2 = 0.06$), showing that XX genotype in defenders had lower hamstring strength than other genotype groups in each tested speed and XX genotype

FIG. 1. Quadriceps and hamstring strength for ACTN3 R577X genotypes and speeds of contraction in soccer player positions. †Significantly higher than other genotype groups at defined playing position and speed of contraction. †† significantly higher than other genotypes groups at all speeds of contraction regardless of playing-position. *Significantly lower than other genotype groups at defined playing position and speed of contraction. ** Significantly lower than other genotypes groups at all speeds of contraction regardless of playing position. †† Significantly lower than other genotype groups in midfielders at 300° speed of contraction. Significance is according to ANOVA and HSD test.

FIG. 2. Quadriceps and hamstring strength for AMPD1 C34T genotypes at high contraction speed. *Significantly lower than other genotypes in the playing position. ** Significantly lower than different genotypes regardless of playing position. Significance is according to ANOVA and HSD test.
had lower hamstring strength than other genotype groups in midfielders at 300°/s speed (Figure 1).

The ANOVA showed differences in AMPD1 genotypes for hamstrings (F₁, 176 = 13.9, p < 0.001, \( \mu^2 = 0.073 \)) and quadriceps (F₁, 176 = 4.99, p = 0.027, \( \mu^2 = 0.027 \)) at 300°/s in whole cohort, where CT genotype resulted in lower relative strength than CC genotype. The differences in AMPD1 by playing positions were found for hamstrings relative strength (F₁, 170 = 3.2, p = 0.025, \( \mu^2 = 0.0754 \)) and quadriceps relative strength (F₁, 170 = 6.14, p = 0.014, \( \mu^2 = 0.034 \)) at 300°/s, where CT heterozygotes showed lower relative hamstring strength in attackers, defenders and midfielders and lower relative quadriceps strength in attackers than CC homozygotes (Figure 2).

The differences in NOS3 genotypes for quadriceps absolute strength were found at speeds 60°/s (F₁, 175 = 8.85, p = 0.003, \( \mu^2 = 0.048 \)) and 180°/s (F₁, 175 = 4.93, p < 0.027, \( \mu^2 = 0.027 \)) in whole cohort, where Glu/Glu homozygotes showed higher strength than Glu/Asp heterozygotes (Figure 3). The differences in NOS3 genotypes by playing positions were found for quadriceps strength at speeds 60°/s (F₁, 169 = 8.32, p = 0.004, \( \mu^2 = 0.046 \)), 180°/s (F₁, 169 = 5.26, p = 0.023, \( \mu^2 = 0.030 \)), where Glu/Glu homozygotes showed higher strength in attackers, defenders and goalkeepers than Glu/Asp heterozygotes (Figure 3).

The differences in IL1RN genotypes and playing position were found for quadriceps absolute strength at speeds 60°/s (F₁, 167 = 6.9, p = 0.009, \( \mu^2 = 0.040 \)), 180°/s (F₁, 167 = 7.06, p < 0.009, \( \mu^2 = 0.041 \)) and 300°/s (F₁, 167 = 4.83, p < 0.029, \( \mu^2 = 0.029 \)), where IL1RN*2 allele carriers (IL1RN*1/IL1RN*2 + IL1RN*2/IL1RN*2) resulted in higher strength than IL1RN*1/IL1RN*1 homozygotes in attackers and goalkeepers (Figure 4). The differences in IL1RN genotypes in context of playing position have been found for quadriceps strength at 300°/s (F₁, 158 = 4.8, p = 0.029, \( \mu^2 = 0.029 \)), where IL1RN*2 allele carriers resulted in higher strength than IL1RN*1/IL1RN*1 in attackers and defenders (Figure 4).

We found no differences between tested phenotype traits in our soccer players concerning their playing position and genotypes for ACE (I/D, rs1799752), UCP2 (Ala55Val, rs660339), BDKRB2 (+9/-9, rs5810761).

FIG. 3. Quadriceps strength for NOS3 Glu298Asp genotypes and speeds of contraction in soccer player positions. *Significantly higher than other genotypes in the playing position according to ANOVA and HSD test.

FIG. 4. Quadriceps and hamstring strength for IL1RN genotypes and speeds of contraction in soccer player positions. *Significantly higher than other genotypes in the playing position according to ANOVA and HSD test.
Speed and power genes in soccer players

**Polygenic study**

The TGSsig included four genotypes (IL1RN, AMPD1 C34T, ACTN3 R577X, and NOS3 Glu298Asp) based on ANOVA results. Those TGSsig genotypes correlated with jump height in countermovement jump, squat jump, relative quadriceps strength at 60°/s, 300°/s, and hamstring strength at 300°/s by $r = 0.19, 0.20, 0.25, 0.20, \text{ and } 0.19$; respectively. Further linear-regression model of TGS including countermovement jump height, squat jump height, relative quadriceps strength at 60°/s, 300°/s, and hamstring strength at 300°/s can explain 19% of this phenotype variance ($R^2 = 0.19, p = 0.009$, Table 3).

The TGS of all seven analyzed genotypes correlated with jump height in countermovement jump, squat jump, relative quadriceps strength at 60°/s, 300°/s, and hamstring strength at 300°/s by $r = 0.30, 0.24, 0.24, 0.27,$ and 0.30; respectively. Further linear-regression model of TGS including countermovement jump height, squat jump height, relative quadriceps strength at 60°/s, 300°/s, and hamstring strength at 300°/s can explain 26% of this phenotype variance ($R^2 = 0.26, p = 0.005$, Table 3).

**DISCUSSION**

Soccer belongs to the sport where speed is one of the main factors defining the difference between an excellent and an average athlete. Under this assumption, monitoring the lower extremities’ maximum strength on an isokinetic dynamometer is a non-invasive and indirect way to determine a predictor of speed capability [43, 44]. Our findings confirm the genetic connection to power-speed performance in soccer players’ positions in four out of seven previously reported gene polymorphisms [45], where ACTN3 had the most evident influence, including the phenotypes of both hamstring and quadriceps strength at all three speeds of contractions. Moreover, our results confirm the previous finding that TGS is associated with professional soccer players [32] and can predict the jump performance [46], where we are adding the TGS link to the muscle strength at different speeds of contractions (regardless of players’ position). An interesting result was that our TGS score of seven selected genotypes had more robust model prediction than TGSsig, including four genotypes. This confirms the major idea of TGS calculation that optimal genotypes profile for certain sport-related phenotypes requires multiple polymorphisms combinations, which are-related phenotypes that require multiple polymorphisms combinations related to different phenotype traits [46].

According to previous studies [7], our results confirm that the ACTN3 RR genotype is associated with speed, power, and strength in elite athletes. With other conditioning assumptions, this genotype can be one of the player’s premises [47], especially the in defenders. Conversely, the ACTN3 XX genotype seems to be related to a less pronounced phenotype in speed, power, and strength predispositions, which we observed in midfielders (Figures 1 and 2). Moreover, the ACTN3 XX genotype is possibly disadvantageous for attackers who did not contain any elite athlete in our cohort. This result corresponds

### TABLE 3. The multiple backward regression for correlated phenotypes in all analyzed genes (TGS) and four significant genotypes (TGSsig).

| Phenotypes                                                                 | b       | SE    | t      | p      |
|---------------------------------------------------------------------------|---------|-------|--------|--------|
| **Jump height:** countermovement jump                                      | Whole model | 2.25  | 0.31   | 10.02  | 0.005  |
|                                                                            | ACE (I/D)| 0.15  | 0.14   | 2.21   | 0.030  |
|                                                                            | BDKRB2 (9/+9)| 0.22 | 0.18   | 2.54   | 0.013  |
|                                                                            | NOS3 (Glu298Asp) | 0.38 | 0.14   | 4.20   | 0.001  |
|                                                                            | IL1RN (VNTR86-bp) | 0.24 | 0.16   | 2.61   | 0.011  |
| **Relative strength:** quadriceps 60°/s and 300°/s                         | AMPD1 (C34T)| 0.18 | 0.13   | 1.60   | 0.112  |
|                                                                            | UCP2 (Ala55Val)| 0.19 | 0.16   | 2.32   | 0.023  |
|                                                                            | ACTN3 (R577X) | 0.12 | 0.15   | 1.62   | 0.109  |
|                                                                            | TGS *  | -0.02 | 0.28  | -2.07  | 0.042  |
| **Jump height:** countermovement jump                                      | Whole model | 2.50  | 0.20   | 12.68  | 0.001  |
|                                                                            | NOS3 (Glu298Asp) | 0.32 | 0.10   | 3.37   | 0.001  |
|                                                                            | IL1RN (VNTR86-bp) | 0.16 | 0.09   | 1.76   | 0.083  |
| **Relative strength:** quadriceps 60°/s and 300°/s                         | AMPD1 (C34T)| 0.14 | 0.11   | 1.27   | 0.209  |
|                                                                            | ACTN3 (R577X) | 0.09 | 0.08   | 1.09   | 0.277  |
|                                                                            | TGSsig ** | -0.01 | 0.00  | -1.17  | 0.246  |

SE = standard error, * explained phenotype variance $R^2 = 0.26, p = 0.005$, ** explained phenotype variance $R^2 = 0.19, p = 0.009$. 

---

Biology of Sport, Vol. 39 No2, 2022 361
to the link between the ACTN3 gene and muscle fiber type II, where the mutated X allele, especially of XX genotype, is less frequent in sprint and power athletes [48–50]. The physiological effect of the ACTN3 X allele leading to missing protein on the structural properties of the sarcomere is described elsewhere [48, 51]. ACTN3 gene coding alpha-actinin-3 protein belongs to groups of α-actinin isoforms, which are one of the main components of Z-line in muscle fiber [52], these form dimers that cross-link actin filaments. Expression of the ACTN3 gene is restricted only to type 2 fibers; thus, muscle fibers containing α-actinin-3 can achieve higher absorption and transfer of force potential in Z-lines during rapid contractions [53]. The main difference in playing position is the distance cover requirements in the soccer match, where midfielders track greater distance than attackers and defenders [54, 55]. Specifically, the central midfielders spend less time in maximum sprints [54]. On the other hand, there is also a record that midfielders have the highest number of acceleration and deceleration activities in the most physically demanding period (10 min) over a game [56].

Our results also show a connection between IL1RN*2 allele carriers and the speed, power, and strength hamstrings in attackers and goalkeepers and quadriceps strength in attackers and defenders; these carriers achieve increased strength levels. Thus IL1RN*2 allele carriers probably relate more to the speed predispositions, which is typical for attackers sprinting or fast goalkeeper reactions. In the past, the VNTR polymorphism in the IL1RN gene was associated with athlete status; the IL1RN*2 allele frequency was increased in professional athletes compared to amateur athletes with training times less than 10 hours a week [57]. Caucci et al. (2010) [57] also suggest that the IL1RN*2 alleles may favor adaptation to high-intensity exercise. Unfortunately, a comparison of our cohort soccer players’ allele/genotype frequencies with controls was not possible due to the unavailability of genotyping for this polymorphism in the control group.

Our study also indicates a connection between NOS3 Glu298Asp polymorphism and the measured parameters of lower limb strength/power. NOS3 Glu/Glu homozygotes showed a higher level of strength in the attackers, defenders, and goalkeepers than Glu/Asp heterozygotes. This polymorphism’s possible effect on sports performance is related to the differential expression of endothelial NO synthase and the production of NO [58]. Our findings are consistent with [59] higher frequencies of the Glu298 allele in speed-strength-trained athletes than controls [59].

Finally, AMPD1 CT heterozygotes resulted in lower relative strength than CC homozygotes, while rare TT homozygotes were completely missing in our cohort. Nucleotide change C to T at position 34 in exon 2 (34C/T) leads to a nonsense codon mutation (Gln12X) prematurely terminating translation associated with AMP deaminase enzyme deficiency. Several studies consistently showed lower T allele frequencies in athletes compared to controls [60, 61].

No relationship has been found between tested strength/power parameters and genotypes for ACE (I/D, rs1799752), UCP2 ( Ala 55Val, rs660339), BDKRB2 (+9/-9, rs5810761); therefore, we suggest no significant contribution of these genetic variants on power and strength of lower limbs in our group soccer players. These findings are not exceptional as there is an inconsistency between genetic influence and speed/power performance in the literature for all mentioned polymorphisms [62–64].

Many studies evaluate the effects of genetic variants on elite (or sub-elite) soccer status [28, 65] or different traits that might be advantageous for soccer performance, including speed and power [66], endurance [67], or injury prevention [68]. For a comprehensive overview, current systematic reviews of McAuley et al. (2020) [7] or Sarmento et al. (2020) [69] suggest several gene variants, which can be beneficial for soccer and specifically for playing position in soccer as our findings exhibit. Nevertheless, sports scientists should keep in mind several things when interpreting the presented results, especially the noncoding biological variability, which continues to be uncovered in the human genome (e.g., epigenetic modifications, microRNAs, etc.). These other types of variability may contribute significantly to differences in athletic performance [70].

CONCLUSIONS

The strength and power measures are higher in elite soccer attackers and defenders, where some genetic markers can support these findings. Specifically, the ACTN3 RR and NOS3 Glu/Glu homozygotes and IL1RN*2 allele carriers have higher strength and power, and thus they seem to be pre-disposed to those attacker or defender playing positions. The midfielders have lower strength and power conditions than other players without relation to “strength and power genes.” The total genetic score regression explained 26% of the jump performance variance and isokinetic strength regardless of playing position.

Funding

Charles University, project GA UK No 180217, UNCE/HUM/032 and Czech science foundation no GA19-12150S

Acknowledgement

The study was supported by the Charles University, project GA UK No 180217, UNCE/HUM/032 and Czech science foundation no GA19-12150S.

Authors’ contributions

All authors met the authorship criteria for this journal and each author made a significant contribution to the final version of this paper.
REFERENCES

1. Rampinini E, Bishop D, Marcra S, Bravo DF, Sassi R, Impellizzeri F. Validity of simple field tests as indicators of match-related physical performance in top-level professional soccer players. Int J Sports Med. 2007;28:228–235.

2. Gissi I, Papadopoulos C, Kalapotharakos VI, Sotiropoulos A, Komsis G, Manolopoulos E. Strength and speed characteristics of elite, subelite, and recreational young soccer players. Res Sports Med. 2006;14:205–214.

3. Pietraszewski P, Gofas A, Matusiński A, Mrzygłód S, Mosliwok A, Maszczyk A. Muscle Activity Asymmetry of the Lower Limbs During Sprinting in Elite Soccer Players. J Hum Kinet. 2020; 75:239–245.

4. Chen Y, Wang D, Yan P, Yan S, Chang Q, Cheng Z. Meta-analyses of the association between the PPARGC1A Gly482Ser polymorphism and athletic performance. Biol Sport. 2019; 36:301–309.

5. Vigne G, Gaudino C, Rogowski I, Aioliatti G, Hautier C. Activity profile in elite Italian soccer team. Int J Sports Med. 2010;31:304–10.

6. Olivo-Lozano JM, Gómez-Carmona CD, Pino-Ortega J, Moreno-Pérez V, Rodríguez-Pérez MA. Match and training high intensity activity-demands profile during a competitive mesocycle in youth elite soccer players. J Hum Kinet. 2020;75:195–205.

7. McAuley AB, Hughes DC, Tsaprouni LG, Varley I, Suraci B, Roos TR, et al. Genetic association research in football: a systematic review. Eur J Sport Sci. 2020;1:1–52.

8. Pickering C, Suraci B, Semenova EA, Beuret-Blanquart F, Kostyukova ES, Kulemin NA, et al. A Genome-Wide Association Study of Sprint Performance in Elite Youth Football Players. J Strength Cond Res. 2019;33:2344–2351.

9. Coelho DB, Pimenta E, Rosse IC, Veneroso C, Becker LK, Carvalho MR, et al. The alpha-actinin-3 r577x polymorphism and physical performance in soccer players. J Sports Med Phys Fitness. 2016;56:241–8.

10. Guilherme JP, Bosnýák E, Semenova E, Szmodis M, Griff A, Móra Á, et al. The MCT1 gene Glu490Asp polymorphism (rs1049434) is associated with endurance athlete status, lower blood lactate accumulation and higher maximum oxygen uptake. Biol Sport. 2021;38:465–474.

11. Lewis MI, Fournier M, Wang H, Storer TW, Casaburi R, Koppel JD. Effect of endurance and/or strength training on muscle fiber size, oxidative capacity, and capillarity in hemodialysis patients. J Appl Physiol. 2015;119:865–871.

12. Hamada T, Sale DG, MacDougall JD, Tarnopolsky MA. Postactivation potentiation, fiber type, and twitch contraction time in human knee extensor muscles. J Appl Physiol. 2000;88:2131–2137.

13. Booyse MJ, West N, Constantinou D. P-85 The relationships of eccentric and concentric isokinetic strength with sprinting speed in male sub-elite footballers. Br J Sports Med. 2016; 50:A79.

14. Corretti G, Maffiulli N, Pousson M, Chatard J-C, Maffulli N. Isokinetic strength and anaerobic power of elite, subelite and amateur French soccer players. Int J Sports Med. 2001; 22:45–51.

15. Cotte T, Chatard J. Isokinetic strength and sprint times in English premier league football players. Biol Sport. 2011; 28:89–94.

16. Harper D, Jordan A, Kiely J. Relationships between eccentric and concentric knee strength capacities and maximal linear deceleration ability in male academy soccer players. J Strength Cond Res. 2021; 35:465–472.

17. Tourny-Chollet C, Leroy D, Léger H, Beuret-Blanquart F. Isokinetic knee muscle strength of soccer players according to their position. Isokinetics and exercise science. 2000;8:187–193.

18. Slivowski R, Grygorowicz M, Hojszyk R, Jadczyk Ł. The isokinetic strength profile of elite soccer players according to playing position. PLoS One. 2017;12:e0182177.

19. Stastny P, Lhehnert M, Tufano JJ. Muscle Imbalances: Testing and Training Functional Eccentric Hamstring Strength in Athletes with Populations. JoVE. 2018:e57508.

20. Chauouchi A, Manzi V, Chalali A, Wong DP, Chamari K, Castagna C. Correlation between quadriceps and hamstrings inter-limb strength asymmetry with change of direction and sprint in U21 elite soccer-players. Hum Mov Sci. 2018;59:81–87.

21. Mallo J, Mena E, Nevado F, Paredes V. Physical demands of top-class soccer players. J Strength Cond Res. 2021;35:465–472.

22. Coratella G, Beato M, Schena F. Correlation between quadriceps and hamstrings inter-limb strength asymmetry with change of direction and sprint in U21 elite soccer-players. Hum Mov Sci. 2018;59:81–87.

23. Modric T, Versic S, Sekulic D, Liposek S. The alpha-actinin-3 r577x gene length polymorphism and performance in professional footballers. Isokinetics and exercise science. 2000;8:187–193.

24. Boone J, Vaeyens R, Steyaert A, Bossche LV, Bourgeois J. Physical fitness of elite Belgian soccer players by player position. J Strength Cond Res. 2012;26:2051–2057.

25. Boracyżyński M, Boracyżyński T, Podstawski R, Wójcik Z, Gronke P. Relationships Between Measures of Functional and Isometric Lower Body Strength, Aerobic Capacity, Anaerobic Power, Sprint and Countermovement Jump Performance in Professional Soccer Players. J Human Kinet. 2020; 75:161–175.

26. Massidda M, Mendez-Villanueva A, Ginevičienė V, Proia P, Dorożdówka SB, Dosenko V, et al. Association of Monocarboxylate Transporter-1 (MCT1) A1470T Polymorphism with Forward Football Player Status. Int J Sports Med. 2018;39:1028–1034.

27. Petr M, Maciejewsk-Skrendo A, Zajac A, Chyckí J, Stastny P. Association of Elite Status with Gene Variants of Peroxisome Proliferator Activated Receptors and Their Transcriptional Coactivator. Int J Mol Sci. 2020;21:162.

28. Santiago C, Gonzalez-Freire M, Serratoa L, Morale FJ, Meyer T, Gomez-Gallego F, et al. ACTN3 genotype in professional soccer players. Br J Sports Med. 2008;42:71–73.

29. Honapour A, Mohseni M, Hajaigha SG, Irani S, Najmabadi H. Investigation of the relationship between a genetic polymorphism in ACTN3 and elite sport performance among Iranian soccer players. Iranian Rehabilitation Journal. 2017;15:149–154.

30. Coelho DB, Pimenta EM, Rosse IC, de Castro BM, Becker LK, de Souza Filho EC, et al. Evidence for a Role of ACTN3 R577X Polymorphism in Football Player’s Career Progression. Int J Sports Med. 2018;39:1088–1093.

31. Pimenta EM, Coelho DB, Veneroso CE, Barros Coelho EJ, Cruz IR, Morandi RF, et al. Effect of ACTN3 gene on strength and endurance in soccer players. J Strength Cond Res. 2013;27:3286–3292.

32. Egorova ES, Borisova AV, Mustafina LJ, Arkhipova AA, Gabbasov RT, Druzhevskaya AM, et al. The polygenic contribution of muscle strength and endurance in soccer players. Iranian Rehabilitation Journal. 2017;15:149–154.

33. Proia P, Bianco A, Schiera G, Saladino P, Massidda M, Proia P, et al. Association of Monocarboxylate Transporter-1 (MCT1) A1470T Polymorphism with Forward Football Player Status. Int J Sports Med. 2018;39:1028–1034.

34. Biolog of Sport, Vol. 39 No2, 2022
46. Weyerstrass J, Stewart K, Wessellius A, Zeegers M. Nine genetic polymorphisms associated with power athlete status – A Meta-Analysis. J Sci Med Sport. 2018; 21:213–220.

36. Alvarez-Romero J, Vosin S, Eynon N, Hiam D. Mapping Robust Genetic Variants Associated with Exercise Responses. Int J Sports Med. 2020; 42:3–18.

37. Wang G, Mikami E, Chiu LL, A DEP, Deason M, Fuku N, et al. Association analysis of ACE and ACTN3 in elite Caucasian and East Asian swimmers. Med Sci Sports Exerc. 2013; 45:892–900.

38. Cieszczyk P, Kalinski M, Ostanek M, Jascienni M, Krupceki F, Kicek F, et al. Variation in the HIF1A gene in elite rowers. J Strength Cond Res. 2012; 26:3270–3274.

39. Sawczuk M, Timshina YI, Astratenkova IV, Maciejewska-Karłowska A, Leorcks-Duncie A, Ficke K, et al. The -9/-9 Polymorphism of the Bradykinin Receptor Beta 2 Gene and Athlete Status: A Study Involving Two European Cohorts: BIOONE; Hum Biol 2013;85:741–755.

40. Maciejewska A, Sawczuk M, Cieszczyk R, Mozhaykskaya IA, Ahmetov, II. The PPARGC1A gene Gly482Ser in Polish women with different ACTN3 R577X genotypes. J Appl Physiol. 2009; 106:959–965.

51. North KN, Yang N, Watters, J, Chmura J, Pluta B, et al. Differential expression of the actin-binding proteins, alpha-actinin-2 and -3, in different species: implications for the evolution of functional redundancy. Hum Mol Genet. 2001; 10:1335–1346.

52. Blanchard A, Ohanian V, Critchley D. The structure and function of g-actinin. J Muscle Res Cell Motil. 1989; 200:280–289.

53. Mills M, Yang N, Weinberger R, Vander Woude DL, Beggs AH. A common nonsense mutation results in alpha-actinin-3 deficiency in the general population. Nat Genet. 1999;1:353–354.

54. Di Salvo V, Baron R, Tschan H, Montero FC, Bach N, Piggozi F. Performance characteristics according to playing position in elite soccer. Int J Sports Med. 2007;28:222–227.

55. Andrejewski M, Chmura J, Pluta B, Konarski JM. Sprinting activities and distance covered by top level Europa league soccer players. International Journal of Sports Science & Coaching. 2015;10:39–50.

56. Martin-Garcia A, Casamichana D, Díaz AG, Cos F, Gabbett TJ. Positional differences in the most demanding passages of play in football competition. J Sports Sci Med. 2018;17:563.

57. Cauci S, Di Santolo M, Ryckman KK, Williams SM, Banfi G. Variable number of tandem repeat polymorphisms of the interleukin-1 receptor antagonist gene IL-1RN: a novel association with the athlete status. BMC Med Genet. 2010;11:29.

58. Dosenko VE, Zagoriy VY, Haytovich NV, Gorkov OA, Molbenko AA. Allelic polymorphism of endothelial NO-synthase gene and its functional manifestations. Acta Biochimica Polonica. 2006;53:299–302.

59. Sessa F, Chetta M, Petito A, Franzetti M, Bafunno V, Pisaneli D, et al. Gene polymorphisms and sport attitude in Italian athletes. Genetic testing and molecular biomarkers. 2011; 15:285–290.

60. Cieszczyk P, Eider J, Ostanek M, Leonska-Duncie A, Ficke K, Kotarska K, et al. Is the CS4T polymorphism of the AMPD1 gene associated with athlete performance in rowing? Int J Sports Med. 2011; 32:987–991.

61. Fedotovskaya ON, Danilova AA, Ahmetov, II. Effect of AMPD1 gene polymorphism on muscle activity in humans. Bull Exp Biol Med. 2013; 154:489–491.

62. Scott RA, Irving R, Irwin L, Morrison E, Charlton V, Austin K, et al. ACTN3 and ACE genotypes in elite Jamaican and US sprinters. Med Sci Sports Exerc. 2010; 42:107–112.

63. Eynon N, Hanson ED, Lucia A, Houweiling PJ, Garton F, North KN, et al. Genes for elite power and sprint performance: ACTN3 leads the way. Sports Med. 2013;43:803–817.

64. Eynon N, Meckel Y, Alves AJ, Nemet D, Eliakim A. Is there an interaction between BDKB2R−9/+ and GNB3 C825T polymorphisms and elite athletic performance? Scand J Med Sci Sports. 2011;21:e242–6.

65. Eynon N, Ruiz JR, Yvert T, Santiago C, Gómez-Gallego F, Lucia A, et al. The C allele in NO3−786 T/C polymorphism is associated with elite soccer player’s status. Int J Sports Med. 2012; 33:521–524.

66. Massidda M, Corrias L, Ibba G, Scorcuc M, Vona G, Calò CM. Genetic markers and explosive leg-muscle strength in elite Italian soccer players. J Sports Med Phys Fitness. 2012; 52:328–234.

67. Dinç N, Yücel SB, Taneli F, Sayın MV. The effect of the MTHFR C677T mutation on athletic performance and the homocysteine level of soccer players and sedentary individuals. J Hum Genet. 2015;61:61–69.

68. Lulinska-Kuklik E, Rahim S, Domanska-Sendorowska D, Ficke K, Michalowska-Sawczyn M, Moska W, et al. Interactions between COL5A1 Gene and -3, in different species: implications for the evolution of functional redundancy. Hum Mol Genet. 2001; 10:1335–1346.

69. Marco AP, Fyfe J, Hackett P, et al. Genetic influence on football performance: Karger Medical and Scientific Publishers; 2016.
SUPPLEMENTARY MATERIAL

**FIG. S1.** Quadriceps and hamstring strength at different speeds in the soccer player group. *Significantly lower than other playing position groups at a defined speed of contraction according to ANOVA and HSD test.

**TABLE S1.** The characteristic of the subjects

| All soccer players: | 99 |
|---------------------|----|
| – Goalkeepers       | 14 |
| – Defenders         | 31 |
| – Midfielders       | 39 |
| – Attackers         | 15 |
| Age (y)             | 25.4 ± 4.51 |
| Height (cm)         | 181.4 ± 6.11 |
| Weight (kg)         | 77.4 ± 7.22 |

**TABLE S2.** Quantity of the components used for the PCR

| Genotype               | DNA (µl) | DNA polymerase (µl) | Attackers primer/reverse primer (µl) | Buffer (µl) | dNTP (µl) | MgCl2 (µl) | Distilled H2O (µl) | Betain (µl) |
|------------------------|----------|--------------------|--------------------------------------|-------------|-----------|------------|-------------------|-------------|
| *ACE* (I/D)            | 2        | Phusion 0,2        | 1                                    | 5xGC Buffer 4 | 4         | Buffer included | 3,8               | 4           |
| *ACTN3* (R577X)        | 2        | Phusion 0,2        | 1                                    | 5xGC Buffer 4 | 4         | Buffer included | 3,8               | 4           |
| *BDKRB2* (9/+9)        | 2        | Phusion 0,2        | 1                                    | 5xGC Buffer 4 | 4         | Buffer included | 3,8               | 4           |
| *NOS3* (Glu298Asp)     | 2        | Phusion 0,2        | 1                                    | 5xGC Buffer 4 | 4         | Buffer included | 3,8               | 4           |
| *AMPD1* (Gln12X)       | 2        | Taq(5U/µl) 0,9     | 0,8                                  | 10xTaq Buffer with KCl 2,0 | 1,5 | 25mM MgCl2,1,6 | 6,4               | 4           |
| *UCP2* (Ala55Val)      | 2        | Taq(5U/µl) 0,4     | 0,8                                  | 10xTaq Buffer with KCl 2,0 | 6    | 25mM MgCl2,1,6 | /                | 4           |
| *IL1RN* (VNTR 86-bp)   | 2        | Phusion 0,2        | 1                                    | 5xGC Buffer 4 | 4         | Buffer included | 3,8               | 4           |
| Genotype     | Forward primer (5’–3’) | Reverse primer (5’–3’) | PCR reaction conditions               |
|--------------|------------------------|------------------------|---------------------------------------|
| **ACE**      | CTGGAGAGCCCACCCCACCTTTTCT | GACGTGGCCATCACATTCGTCAGAT | Denaturation: 98°C 30 s – 72°C 30 s  |
| (I/D)        |                        |                        | Annealing and cycles: 98°C 10 s – 35 cycles |
| **ACTN3**    | CTGTTGCTGTTGTAAGTAGGG  | TGGTCACAGTATGCAGGAGGG   | Denaturation: 94°C 30 s                |
| (R577X)      |                        |                        | Annealing and cycles: 70°C 1 min – 35 cycles |
| **BDKRB2**   | TCCAGCTGCTGTGCTTTCTG   | AGTCGCTCCCTGACTGC       | Denaturation: 98°C 30 s – 72°C 30 s   |
| (9/+9)       |                        |                        | Annealing and cycles: 68°C 30 s – 35 cycles |
| **NOS3**     | CATGAGGCTCAGCCCCAGAAC  | AGTCAATCCCTTTGCTCAC     | Denaturation: 98°C 30 s – 72°C 10 s   |
| (Glu298Asp)  |                        |                        | Annealing and cycles: 62°C 30 s – 35 cycles |
| **AMPD1**    | TCTTACAGCTGAAGAGACA    | GAAATCAGAAAAACCATGAG   | Denaturation: 95°C 30 s – 72°C 5 min  |
| (Gln12X)     |                        |                        | Annealing and cycles: 56,4°C 1 min    |
| **UCP2**     | TGGGAGTCTTGATGTGTCTAC  | CACCCGGTACTGGCGCTG     | Denaturation: 95°C 30 s – 72°C 5 min  |
| (Ala55Val)   |                        |                        | Annealing and cycles: 61,2°C 50 s    |
| **IL1RN**    | CTCAGCAACACCTCTAT      | TCCTGGCTCAGGTAA        | Denaturation: 98°C 30 s – 72°C 5 min  |
| (VNTR 86-bp) |                        |                        | Annealing and cycles: 57°C 30 s    |